Author: Violi, Francesco; Pastori, Daniele; Cangemi, Roberto; Pignatelli, Pasquale; Loffredo, Lorenzo
Title: Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge Cord-id: gfoejvb3 Document date: 2020_4_29
ID: gfoejvb3
Snippet: The novel coronavirus 2019 (COVID-19) is clinically characterized by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for a high number of patients needing mechanical ventilation or intensive care units treatment and for the elevated mortality risk. A link between COVID-19 and multiorgan failure may be dependent on the fact that most COVID-19 patients are complicated by pneumonia, which is known to be associated with early changes of clotting and platelet activa
Document: The novel coronavirus 2019 (COVID-19) is clinically characterized by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for a high number of patients needing mechanical ventilation or intensive care units treatment and for the elevated mortality risk. A link between COVID-19 and multiorgan failure may be dependent on the fact that most COVID-19 patients are complicated by pneumonia, which is known to be associated with early changes of clotting and platelet activation and artery dysfunction; these changes may implicate in thrombotic-related events such as myocardial infarction and ischemic stroke. Recent data showed that myocardial injury compatible with coronary ischemia may be detectable in SARS-CoV-2 patients and laboratory data exploring clotting system suggest the presence of a hypercoagulation state. Thus, we performed a systematic review of COVID-19 literature reporting measures of clotting activation to assess if changes are detectable in this setting and their relationship with clinical severity. Furthermore, we discussed the biologic plausibility of the thrombotic risk in SARS-CoV-2 and the potential use of an antithrombotic treatment.
Search related documents:
Co phrase search for related documents- absolute value and acute phase: 1
- abstract title and acute ards respiratory distress syndrome: 1
- abstract title and acute phase: 1, 2, 3, 4, 5, 6, 7
- abstract title and acutely ill: 1, 2
- abstract title and lmwh low molecular weight heparin: 1
- abstract title and local systemic: 1
- abstract title and low molecular weight: 1
- abstract title and low molecular weight heparin: 1
- acute ards respiratory distress syndrome and liver failure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- acute ards respiratory distress syndrome and lmwh low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7
- acute ards respiratory distress syndrome and lmwh prophylactic dose: 1
- acute ards respiratory distress syndrome and lmwh prophylaxis: 1, 2
- acute ards respiratory distress syndrome and local systemic: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- acute ards respiratory distress syndrome and low molecular weight: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- acute ards respiratory distress syndrome and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- acute phase and lmwh prophylaxis: 1
- acute phase and local systemic: 1, 2, 3, 4, 5
- acute phase and low molecular weight: 1, 2, 3, 4, 5, 6, 7
- acute phase and low molecular weight heparin: 1, 2, 3, 4, 5, 6
Co phrase search for related documents, hyperlinks ordered by date